- / 2011
Denosumab Effective Shared Care Agreement Toolkit Launched Online
A new online resource – designed to assist healthcare professionals in the local development of shared care agreements for denosumab (Prolia®) – has been launched by Medicines Management at Keele University.
The Effective Shared Care Agreement Toolkit (http://www.esca-keele.co.uk/denosumab/) outlines clinical and patient management responsibilities and suggests how they can be shared between the secondary care specialist and general practitioner / primary care prescriber. Acting as a flexible template, the Toolkit enables users to consider proposed content relevant to denosumab – key principles, monitoring requirements, dosage and administration, contraindications, interactions, etc., – and tailor it to their local circumstances and requirements. (Content is consistent with both NICE guidance and the denosumab summary of product characteristics.) Local agreements can be created and edited by ‘dragging and dropping’ pre-prepared content into a unique template document. Each template can then be saved online for further review or downloaded to the user’s own computer.
Professor Stephen Chapman, Professor of Prescribing Studies at Keele University said, “Effective shared care agreements are essential in ensuring consistency of care as drugs move from secondary to primary care. Indeed, their importance will undoubtedly grow as GPs assume greater responsibility in the commissioning of medicines. They are however, time consuming and resource intensive to produce. Providing this electronic template will simplify the process for those healthcare professionals engaged in developing local policy on the use of denosumab.”
The denosumab Toolkit is designed to support healthcare professionals in creating agreements aligned to NICE and locally agreed policy on the prescribing of denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures.
The Toolkit is available at http://www.esca-keele.co.uk/denosumab/.
The Effective Shared Care Agreement Toolkit is not a recommendation to prescribe denosumab. The decision to prescribe denosumab is the responsibility of the respective local healthcare organisation and the Toolkit should only be used after the local decision to prescribe denosumab has been taken.
The development of the Denosumab Effective Shared Care Agreement Toolkit was made possible by an unrestricted grant provided by GlaxoSmithKline and Amgen in the UK.
If you require a screenshot of the Toolkit please contact Simon Thomas at Keele University (email: email@example.com; tel: 01782 715458).